{"id":33523,"date":"2025-05-21T14:11:16","date_gmt":"2025-05-21T12:11:16","guid":{"rendered":"https:\/\/ggba.swiss\/repronovo-raises-usd-65-million-to-advance-trials-in-reproductive-health\/"},"modified":"2025-05-21T14:13:33","modified_gmt":"2025-05-21T12:13:33","slug":"repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/","title":{"rendered":"ReproNovo l\u00e8ve USD 65 millions pour faire avancer ses essais cliniques en sant\u00e9 reproductive"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.repronovo.com\/\">ReproNovo<\/a>, une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la m\u00e9decine reproductive et la sant\u00e9 des femmes, a lev\u00e9 USD 65 millions lors d&rsquo;un tour de financement de s\u00e9rie A. Bas\u00e9e \u00e0 Lausanne, avec des activit\u00e9s de d\u00e9veloppement \u00e0 Copenhague et Barcelone, la soci\u00e9t\u00e9 vise \u00e0 combler des lacunes critiques dans les traitements de la fertilit\u00e9 gr\u00e2ce \u00e0 l&rsquo;avancement de deux programmes cliniques pr\u00eats pour la phase 2.<\/p>\n\n\n\n<p>Le tour de table a \u00e9t\u00e9 men\u00e9 par <a href=\"https:\/\/www.jeito.life\/\">Jeito Capital<\/a> et co-dirig\u00e9 par <a href=\"https:\/\/alts.axa-im.com\/\">AXA IM Alts<\/a> et <a href=\"https:\/\/www.m-ventures.com\/\">M Ventures<\/a>, avec le soutien suppl\u00e9mentaire de <a href=\"https:\/\/ysioscapital.com\/\">Ysios Capital<\/a> et <a href=\"https:\/\/www.alsaventures.com\/\">ALSA Ventures<\/a>. Les fonds serviront \u00e0 soutenir le d\u00e9veloppement clinique en cours et les efforts de mise \u00e0 l&rsquo;\u00e9chelle, en particulier pour les deux principaux candidats de ReproNovo : RPN-001 et RPN-002.<\/p>\n\n\n\n<p>Le RPN-001 (leflutrozole) est un traitement oral en cours de d\u00e9veloppement pour traiter l&rsquo;infertilit\u00e9 chez les hommes pr\u00e9sentant un faible taux de testost\u00e9rone s\u00e9rique, une affection qui touche un nombre croissant d&rsquo;hommes, y compris les populations plus jeunes. Ce traitement offre une approche novatrice en inhibant l&rsquo;activit\u00e9 de l&rsquo;aromatase et en r\u00e9tablissant les niveaux de testost\u00e9rone. La sant\u00e9 reproductive masculine \u00e9tant d\u00e9sormais consid\u00e9r\u00e9e comme un enjeu de sant\u00e9 publique mondial, le besoin de traitements efficaces et accessibles n&rsquo;a jamais \u00e9t\u00e9 aussi grand.<\/p>\n\n\n\n<p>Le RPN-002 (nolasiban) est un antagoniste des r\u00e9cepteurs de l&rsquo;ocytocine, le premier de sa cat\u00e9gorie, qui cible l&rsquo;ad\u00e9nomyose, une affection gyn\u00e9cologique invalidante associ\u00e9e \u00e0 des douleurs intenses et \u00e0 une baisse de la fertilit\u00e9. Le RPN-002 pourrait \u00e9galement am\u00e9liorer les taux de r\u00e9ussite de l&rsquo;implantation d&#8217;embryons dans le cadre des techniques de procr\u00e9ation m\u00e9dicalement assist\u00e9e (PMA), un domaine cl\u00e9 des traitements de fertilit\u00e9 chez la femme. Il n&rsquo;existe actuellement aucun m\u00e9dicament approuv\u00e9 pour ces deux indications.<\/p>\n\n\n\n<p>Fond\u00e9e en 2021, ReproNovo est dirig\u00e9e par Jean Marie Duvall, CEO, Joan-Carles Arce, CSO et CMO, et BingMei Hao, CFO. L&rsquo;\u00e9quipe de direction apporte une vaste exp\u00e9rience dans le domaine de la m\u00e9decine reproductive et du d\u00e9veloppement de m\u00e9dicaments, avec \u00e0 son actif plusieurs programmes cliniques et lancements commerciaux couronn\u00e9s de succ\u00e8s. Soutenue par un solide consortium international, ReproNovo est bien plac\u00e9e pour \u00e9tendre son empreinte clinique et rapprocher ses traitements du march\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La biotech lausannoise ReproNovo a lev\u00e9 USD 65 millions pour faire avancer la phase 2 des essais cliniques de nouveaux traitements contre l&rsquo;infertilit\u00e9 masculine et pour la sant\u00e9 reproductive des femmes.<\/p>\n","protected":false},"author":6,"featured_media":33520,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1188,1171],"class_list":["post-33523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ReproNovo l\u00e8ve USD 65 millions | GGBa<\/title>\n<meta name=\"description\" content=\"ReproNovo a lev\u00e9 USD 65M pour faire avancer la phase 2 des essais cliniques de nouveaux traitements pour la sant\u00e9 reproductive des femmes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ReproNovo l\u00e8ve USD 65 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"ReproNovo a lev\u00e9 USD 65M pour faire avancer la phase 2 des essais cliniques de nouveaux traitements pour la sant\u00e9 reproductive des femmes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T12:11:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T12:13:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"ReproNovo l\u00e8ve USD 65 millions pour faire avancer ses essais cliniques en sant\u00e9 reproductive\",\"datePublished\":\"2025-05-21T12:11:16+00:00\",\"dateModified\":\"2025-05-21T12:13:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/\"},\"wordCount\":412,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/\",\"name\":\"ReproNovo l\u00e8ve USD 65 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg\",\"datePublished\":\"2025-05-21T12:11:16+00:00\",\"dateModified\":\"2025-05-21T12:13:33+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"ReproNovo a lev\u00e9 USD 65M pour faire avancer la phase 2 des essais cliniques de nouveaux traitements pour la sant\u00e9 reproductive des femmes.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"ReproNovo d\u00e9veloppe de nouveaux traitements contre l'infertilit\u00e9 et l'ad\u00e9nomyose avec une \u00e9quipe r\u00e9partie en Suisse, au Danemark et en Espagne. | \u00a9 ReproNovo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ReproNovo l\u00e8ve USD 65 millions pour faire avancer ses essais cliniques en sant\u00e9 reproductive\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ReproNovo l\u00e8ve USD 65 millions | GGBa","description":"ReproNovo a lev\u00e9 USD 65M pour faire avancer la phase 2 des essais cliniques de nouveaux traitements pour la sant\u00e9 reproductive des femmes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/","og_locale":"fr_FR","og_type":"article","og_title":"ReproNovo l\u00e8ve USD 65 millions | GGBa","og_description":"ReproNovo a lev\u00e9 USD 65M pour faire avancer la phase 2 des essais cliniques de nouveaux traitements pour la sant\u00e9 reproductive des femmes.","og_url":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-05-21T12:11:16+00:00","article_modified_time":"2025-05-21T12:13:33+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"ReproNovo l\u00e8ve USD 65 millions pour faire avancer ses essais cliniques en sant\u00e9 reproductive","datePublished":"2025-05-21T12:11:16+00:00","dateModified":"2025-05-21T12:13:33+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/"},"wordCount":412,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg","keywords":["Biotech","Financing","Healthcare","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/","url":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/","name":"ReproNovo l\u00e8ve USD 65 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg","datePublished":"2025-05-21T12:11:16+00:00","dateModified":"2025-05-21T12:13:33+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"ReproNovo a lev\u00e9 USD 65M pour faire avancer la phase 2 des essais cliniques de nouveaux traitements pour la sant\u00e9 reproductive des femmes.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/ReproNovo-65-millions-1180x811-1.jpeg","width":1180,"height":811,"caption":"ReproNovo d\u00e9veloppe de nouveaux traitements contre l'infertilit\u00e9 et l'ad\u00e9nomyose avec une \u00e9quipe r\u00e9partie en Suisse, au Danemark et en Espagne. | \u00a9 ReproNovo"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/repronovo-leve-usd-65-millions-pour-faire-avancer-ses-essais-cliniques-en-sante-reproductive\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"ReproNovo l\u00e8ve USD 65 millions pour faire avancer ses essais cliniques en sant\u00e9 reproductive"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=33523"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33523\/revisions"}],"predecessor-version":[{"id":33525,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33523\/revisions\/33525"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/33520"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=33523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=33523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=33523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}